These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23966785)

  • 21. A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.
    Selvan P; Devkare P; Shetty A; Dharmadhikari S; Khandhedia C; Mane A; Mehta S; Andrade C
    Front Psychiatry; 2024; 15():1385925. PubMed ID: 38711874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of Cariprazine and its Major Metabolites.
    Periclou A; Phillips L; Ghahramani P; Kapás M; Carrothers T; Khariton T
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):53-69. PubMed ID: 33141308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
    Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
    CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study.
    Yeung PP; Johnson KA; Riesenberg R; Orejudos A; Riccobene T; Kalluri HV; Malik PR; Varughese S; Findling RL
    J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):232-242. PubMed ID: 37437109
    [No Abstract]   [Full Text] [Related]  

  • 26. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials.
    Do A; Keramatian K; Schaffer A; Yatham L
    Front Psychiatry; 2021; 12():769897. PubMed ID: 34970166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on schizophrenia and bipolar disorder: focus on cariprazine.
    Roberts RJ; Findlay LJ; El-Mallakh PL; El-Mallakh RS
    Neuropsychiatr Dis Treat; 2016; 12():1837-42. PubMed ID: 27524901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.
    Tarzian M; Ndrio M; Kaja S; Beason E; Fakoya AO
    Cureus; 2023 May; 15(5):e39309. PubMed ID: 37378203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
    De Berardis D; Orsolini L; Iasevoli F; Prinzivalli E; de Bartolomeis A; Serroni N; Mazza M; Valchera A; Fornaro M; Vecchiotti R; Carano A; Sepede G; Vellante F; Matarazzo I; Pompili M; Perna G; Conti C; Segura-García C; Martinotti G; Di Giannantonio M
    Curr Pharm Des; 2016; 22(33):5144-5162. PubMed ID: 27396597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cariprazine in Bipolar Depression and Mania: State of the Art.
    Mazza M; Marano G; Traversi G; Carocci V; Romano B; Janiri L
    CNS Neurol Disord Drug Targets; 2018; 17(10):723-727. PubMed ID: 30152291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine.
    Batinic B; Ristic I; Zugic M; Baldwin DS
    Front Psychiatry; 2021; 12():784370. PubMed ID: 34887792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel atypical antipsychotic cariprazine demonstrates dopamine D
    Delcourte S; Ashby CR; Rovera R; Kiss B; Adham N; Farkas B; Haddjeri N
    CNS Neurosci Ther; 2018 Dec; 24(12):1129-1139. PubMed ID: 29729086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cariprazine for Schizophrenia and Bipolar Disorder.
    Scarff JR
    Innov Clin Neurosci; 2016; 13(9-10):49-52. PubMed ID: 27975000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).
    Ivanov SV; Smulevich AB; Voronova EI; Yakhin KK; Beybalaeva TZ; Katok AA
    Front Psychiatry; 2021; 12():770592. PubMed ID: 35140638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.